China Resources Pharmaceutical | Sustainability Performance
Engages in the research, manufacturing, and distribution of pharmaceutical products across therapeutic areas. It provides medicines and health solutions through retail and hospital channels, supported by domestic and international partnerships.
2007
China
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$500M - 1B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#5257
Overallⓘ#112
in Chinaⓘ#111
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Laggard
Critical
Critical
Intensity
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark
31.2
B/M 42.0
Powered by illuminem and GIST Impact
Controversy level
- China Resources Pharmaceutical Group Limited (CR Pharmaceutical, China Resources statecontrolled), Hong Konglisted Chinese major pharma, has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of Chinese pharma customer compliance practices, plus periodic class actions over alleged inadequate disclosure of Chinese stateaffiliated controlling shareholder governance complexity affecting Hong Konglisted institutional minority shareholders amid Chinese statecontrolled pharma sector regulatory pressure.
